Back to search

Duquesne

DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS

Abstract

dc:description.abstract

Alzheimer's disease (AD) is a progressive neurodegenerative disease that impairs memory and cognitive judgment, mostly in older people. It is the leading cause of dementia in late adult life. The hallmarks of AD include neuronal loss, neuroinflammation, a build-up of extracellular amyloid beta (Aβ) plaques, intracellular neurofibrillary tangles, and extracellular neuritic plaques. Current treatment, although useful, is not adequate. Identification of therapeutic agents with the potential to alter the progress of AD is a high priority. Recent studies suggest that the Sigma-2 receptor is an attractive target for the development of disease-modifying AD drugs. Preventing the binding of Sigma-2 receptors to Aβ oligomers alleviates Aβ-mediated synaptotoxicity in a dose-dependent manner. Using pharmacophore analysis and ligand-based drug design strategies, novel piperazine-containing compounds were designed and synthesized as Sigma-2 receptor antagonists. The MEK5/ERK5 pathway regulates various cellular processes, including proliferation, differentiation, apoptosis, and migration, and is found to be upregulated in various types of cancer. In triple-negative breast cancer (TNBC), upregulation of the MEK5 pathway is linked to resistance development, poorer relapse-free survival, and activation of epithelial-to-mesenchymal transition (EMT). Therefore, MEK5 is a potential therapeutic target for treating breast cancer, especially TNBC. Additionally, in cancer, overexpression of the PI3K/Akt pathway is also linked to enhanced tumor cell survival and proliferation. The PI3K/Akt and MEK pathways are proposed to be interconnected by crosstalk loops. The dual inhibition of PI3K/Akt and MEK5/ERK5 signaling is found to be more effective at reducing the proliferation and survival of TNBCs than the single inhibition of either pathway alone. Therefore, for effective TNBC treatment, the design and development of selective MEK5 and dual MEK5/PI3K inhibitors were pursued. Literature reported quinazoline derivative was used as the lead compound. The homology model of MEK5 was built using the MEK1 structure (3EQC and 7PQV) to assist in drug design. Extensive lead optimization was conducted using medicinal chemistry approaches, which included surveying variations at the C4 and C6 positions of the quinazoline core along with N-alkyl and hinge binder modifications.

Degree

thesis:*
Name thesis:degree_name
PhD
Level thesis:degree_level
One-year Embargo
Discipline thesis:degree_discipline
Medicinal Chemistry

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Patel, Saloni
Contributors dc:contributor
  • Dr. Patrick T. Flaherty
  • Dr. Aleem Gangjee
  • Dr. Marc W. Harold
  • Dr. Jane Cavanaugh
  • Dr. Kevin Tidgewell

Subjects

dc:subject × 9

Rights

Language dc:language
English

Identifiers

dc:identifier.*
Repository record dc:identifier
https://dsc.duq.edu/etd/2348

Chain of custody

source
Harvested from
Duquesne
Base URL
dsc.duq.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Patel, Saloni. DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER AND NEURODEGENERATIVE DISORDERS. One-year Embargo thesis, https://dsc.duq.edu/etd/2348